Over the last 5 years, prophylactic vaccination against human papillomavirus (HPV) in pre-
adolescent females has been introduced in most developed countries, supported by …

Cytology-based screening has reduced cervical cancer mortality in countries able to
implement, sustain and financially support organized programs that achieve broad …

Background Bivalent and quadrivalent human papillomavirus (HPV) vaccines are now
licensed in several countries. Furthermore, clinical trials examining the efficacy of a …

Background. The ongoing development of a vaccine against human papillomavirus (HPV)
raises important questions about the impact of various vaccination strategies. Methods. Two …

Sexually transmitted human papillomavirus (HPV) infection is very common in men and
women. Oncogenic HPV is strongly associated with cancers and high-grade dysplasias of …

The availability of prophylactic human papillomavirus (HPV) vaccines has provided powerful
tools for primary prevention of cervical cancer and other HPV-associated diseases. Since …

Background: A vaccine against human papillomavirus (HPV) types 6, 11, 16 and 18 is now
licensed for use in Canada and many other countries. We sought to estimate the number …

Human papillomavirus (HPV) has been implicated as the primary etiologic agent of cervical
cancer. Potential vaccines against high-risk HPV types are in clinical trials. We evaluated …

Since 2006, 115 countries and territories have introduced human papillomavirus (HPV)
vaccination programs. Several efforts have been undertaken to evaluate the impact of HPV …

We currently have the knowledge and experience to prevent much of human papillomavirus
(HPV)-related disease burden globally. In many countries where prophylactic HPV …